Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431

Etan Orgel; Kristin R Knight; Doojduen Villaluna; Mark Krailo; Adam J Esbenshade; Lillian Sung; David R Freyer

doi:10.1002/pbc.30550

Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431

Pediatr Blood Cancer. 2023 Jul 7:e30550. doi: 10.1002/pbc.30550. Online ahead of print.

Authors

Etan Orgel^{1

2}, Kristin R Knight³, Doojduen Villaluna⁴, Mark Krailo⁵, Adam J Esbenshade⁶, Lillian Sung⁷, David R Freyer^{1

2}

Affiliations

¹ Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
² Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
³ Department of Pediatric Audiology, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, Oregon, USA.
⁴ Children's Oncology Group, Monrovia, California, USA.
⁵ Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
⁶ Division of Pediatric Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁷ Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

Abstract

In two randomized trials (Children's Oncology Group ACCL0431 and International Childhood Liver Tumour Strategy Group SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus International Society of Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. Compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.

Keywords: childhood cancer; cisplatin; hearing loss; ototoxicity; sodium thiosulfate.

Abstract

Grants and funding